147 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
ARRY Array BioPharma Inc. $14.1 $2.97B N/A
Article Searches
Binimetinib Withdrawal Reveals Array Of Issues http://seekingalpha.com/article/4056805-binimetinib-withdrawal-reveals-array-issues?source=feed_all_articles Mar 21, 2017 - The withdrawal of Array Biopharma’s (NASDAQ:ARRY) filing for binimetinib is, on the face of it, not too big a deal. The company had sought approval in Nras-mutant melanoma, a much smaller indication t
Boulder biotech shares rise with 'positive' melanoma drug results http://feeds.bizjournals.com/~r/industry_6/~3/OXEAAkghEhs/boulder-biotech-shares-rise-with-positive-melanoma.html May 10, 2017 - Shares in Array BioPharma Inc. were soaring in early Wednesday trading, even though the company announced a bigger loss and smaller third-quarter revenues compared with last year. That's because the Boulder biotech announced "positive" results from a study of its drug targeting unresectable or metastatic melanoma. The study results "represents a potential important addition to the ... treatment landscape for patients with BRAF-mutant melanoma," said Ron Squarer, CEO, in a statement. Array said…
Biotech Forum Daily Digest - Celgene Continues To Make Deals, Spotlight On Xenon https://seekingalpha.com/article/4086085-biotech-forum-daily-digest-celgene-continues-make-deals-spotlight-xenon?source=feed_all_articles Jul 06, 2017 - Biotech continues to meander in trading amid a dearth of new M&A activity.Biotech stalwart Celgene continues to make significant collaboration deals throughout the industry across myriad disease areas
3 Things In Biotech You Should Learn Today: May 11, 2017 https://seekingalpha.com/article/4072211-3-things-biotech-learn-today-may-11-2017?source=feed_all_articles May 11, 2017 - Roche takes a surprising left in immunotherapy.Array is charting new lands in the COLUMBUS study.Allergan completes enrollment in its wet AMD studies.
Here's Why the Market's Overlooking Array Biopharma Inc.'s Earnings Miss Today https://www.fool.com/investing/2017/05/10/heres-why-the-markets-overlooking-array-biopharma.aspx?source=iedfolrf0000001 May 10, 2017 - Array Biopharma's financial results get the back seat today, while clinical-trial results ride shotgun.
Jim Cramer Shares His Thoughts On Foot Locker, Array Biopharma And Ulta Beauty http://feeds.benzinga.com/~r/benzinga/~3/Lp_N93Sa06g/jim-cramer-shares-his-thoughts-on-foot-locker-array-biopharma-and-ulta-beau Jun 09, 2017 -

Jim Cramer said on CNBC's "Mad Money" that Foot Locker, Inc. (NYSE: FL) didn't have a great quarter so he isn't recommending it as a buy at the moment.

read more

Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers http://seekingalpha.com/article/4057156-best-price-positioned-integrated-oil-and-gas-stocks-seen-market-makers?source=feed_tag_etf_portfolio_strategy Mar 22, 2017 - This is not an attack on the energy industry or its major players.It is a comparison of the views being held by the big-money clients of Market-Makers as to their investment alternatives.It also offer
Former Arris Bull Grows Cautious, Lowers Stock To Equal-Weight http://feeds.benzinga.com/~r/benzinga/~3/ZPpsDR7mJ-4/former-arris-bull-grows-cautious-lowers-stock-to-equal- Dec 19, 2017 -

Despite a 15-percent decline throughout 2017, ARRIS International plc (NASDAQ: ARRS) was still favorably viewed by some on the Street, but on Tuesday a notable analyst changed their previously bullish thesis. 

3 Things In Biotech, July 16: Array Gets An Important Update https://seekingalpha.com/article/4187583-3-things-biotech-july-16-array-gets-important-update?source=feed_all_articles Jul 16, 2018 - Array's melanoma combo gets a guideline nod. Atossa looks for a window of opportunity in breast cancer. Astellas and Pfizer score widened approval for Xtandi.
MyoKardia IPO: Early Stage, Skittish IPO Market Leave Us Hesitant http://seekingalpha.com/article/3606906-myokardia-ipo-early-stage-skittish-ipo-market-leave-us-hesitant?source=feed_tag_ipo_analysis Oct 27, 2015 - SF-based MYOK is a clinical-stage biopharmaceutical, developing therapies for rare and serious cardiovascular diseases. MYOK scheduled a ~$74 million NASDAQ IPO; lead underwriters Cowen & Credit Suiss

Pages: 123456...15

Page 1>

Related Companies

Name Exchange Price Mkt Cap
HRTX Heron Therapeutics, Inc. NASDAQ $38.1 $2.96B
EBS Emergent Biosolutions, Inc. NYSE $59.27 $2.95B
ASND Ascendis Pharma A/S NASDAQ $71.52 $2.99B
MDCO The Medicines Company NASDAQ $39.85 $2.93B
BPMC Blueprint Medicines Corporation NASDAQ $69.69 $3.06B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Array BioPharma